Bi-specific antibodies have gained traction in cancer drug development due to their ability to target two distinct antigens, thereby enhancing therapeutic efficacy simultaneously. They overcome limitations of traditional monoclonal antibodies by redirecting immune effector cells to tumor sites, blocking multiple oncogenic pathways, or bridging tumor cells with cytotoxic T-lymphocytes. Key mechanisms include T-cell engagement through CD3 binding, dual checkpoint inhibition, and simultaneous targeting of resistance pathways. Bi-specific antibodies, however, are challenging to develop and produce. GenScript offers an advanced integrated development platform that addresses development and manufacturing challenges through expedited processes, and novel expression systems and purification strategies, enabling scalable production of stable, potent bi-specific constructs with improved safety profiles and enhanced anti-tumor activity. 

Learning Objectives:

1. Learn about challenges in developing bi-specific antibodies.

2. Learn about methodologies for development.

3. Learn how GenScript's solutions can accelerate your development.